Concert presents positive results of Phase 2 trial for alopecia areata
Category: #healthcare  By Akshay Kedari  Date: 2019-10-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Concert presents positive results of Phase 2 trial for alopecia areata

Alopecia areata, an autoimmune disease that causes hair loss is seen to grow substantially and higher number of people every year. Global pharmaceutical firms are increasingly working towards development of medicines for the treatment of alopecia areata. 

An example of this came to light when Concert Pharmaceuticals, a US based pharmaceutical firm headquartered in Lexington, Massachusetts, committed to find novel therapies for various chronic diseases reportedly showcased positive results from the Phase 2 trial of CTP-543, an investigational medicine administered in patients having moderate to severe alopecia areata.

Patients who were involved in the trial were treated with 12 mg of CTP-543 twice-daily or 8 mg of CTP-543 twice daily, and reached the primary efficacy endpoint along with statistically substantial differences relative to placebo in the patient percentage, obtaining more than or equal to 50 percent relative difference from baseline at 24 weeks by using the SALT (Severity of Alopecia Tool).

The Phase 2 study was a randomized, sequential, double-blind and placebo-controlled dose trial done in order to evaluate the efficacy and safety of CTP-543 in mature patients having moderate-to-severe alopecia areata. 149 adult patients were randomly given CTP-543’s one among three doses or placebo, given twice daily.

The outcomes were showcased in the 28th European Academy of Dermatology and Venereology (EADV) Annual Congress at Madrid, Spain.        

Chief Development Officer at Concert, who also gave the oral representation in EADV, James V. Cassella, Ph.D. stated that the company is delighted that it was selected to showcase its efficacy and safety data for CTP-543 medicine to the community of treatment at this Congress.

Cassella further stated that the company believes the outcomes from this dose-ranging trial along with its oral JAK inhibitor, CTP-543, have set a new limit for clinical outcomes in patients having moderate-to-severe alopecia areata.

Cassella further added that the company looks forward to improving the CTP-543 development into Phase 3 evaluation in 2020, as it continues its efforts to launch a novel treatment for patients diagnosed with this severe autoimmune disorder which has no approved medication presently.

Source credit: https://www.businesswire.com/news/home/20191012005001/en/Concert-Pharmaceuticals-Presents-Positive-Phase-2-Data

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

YouTube found experimenting with embedded shopping links in videos
YouTube found experimenting with embedded shopping links in videos
By Akshay Kedari

The new feature will enable users to directly purchase products shown in videos through the platfo...

Bühler-DIL enter partnership to strengthen alternative proteins R&D
Bühler-DIL enter partnership to strengthen alternative proteins R&D
By Akshay Kedari

In a bid to expand their product portfolio, Swiss multinational plant equipment manufacturer Bü...

Bakery processing equipment to witness increasing demand with innovations in production
Bakery processing equipment to witness increasing demand with innovations in production
By Akshay Kedari

The American Bakers Association (ABA) claims baking companies generate over US$153 billion in econom...